Market Cap: $10.79B
BI
BioMarin Pharmaceutical Inc.
BMRN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $10.79B
BioMarin Pharmaceutical (Ticker: BMRN) showcases significant advancements in rare disease therapies, underpinned by recent presentations at the ENDO 2026 conference. The company highlights promising l…
BioMarin Pharmaceutical Inc. (Ticker: BMRN) continues to make significant strides in addressing growth disorders in children, as highlighted by new data at the recent ENDO 2026 conference in Chicago.…
BioMarin Pharmaceutical (Ticker: BMRN) announces promising results from its Phase 3 clinical trials for VOXZOGO, a treatment designed for children with hypochondroplasia, a rare form of skeletal dyspl…
BioMarin Pharmaceutical Inc. has made significant strides in addressing rare genetic disorders through its innovative research and clinical trials. The company recently provided an update on its Phase…
BioMarin Pharmaceutical (Ticker: BMRN) faces both opportunities and challenges as it navigates the complexities of developing treatments for rare genetic disorders. The recent update on its Phase 3 EN…
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced significant advancements regarding its treatment for achondroplasia, VOXZOGO® (vosoritide), which has become the sole approved therapy for chi…
Creating Awareness for Rare Diseases: CNBC Cures Makes an Impact In an inspiring move to raise awareness for the 30 million Americans affected by rare diseases, CNBC has launched an initiative named "…
Insider Sale Raises Questions Amid BioMarin’s Ongoing Development BioMarin Pharmaceutical, a leader in biotechnology focused on treatments for rare diseases, finds itself in the spotlight following th…
BioMarin’s VOXZOGO® Shows Promising Results in Early Treatment for Achondroplasia BioMarin Pharmaceutical Inc. announces encouraging findings from its studies on VOXZOGO® (vosoritide), which reaffirm…
Advancements in Rare Disease Treatments: A Focus on Biomarin Pharmaceutical In the rapidly evolving landscape of biotechnology, Biomarin Pharmaceutical stands out for its commitment to addressing rare…
Biomarin Pharmaceutical: Pioneering Treatments for Rare Genetic Disorders Biomarin Pharmaceutical stands at the forefront of innovative biopharmaceutical research dedicated to addressing rare genetic…
### Scrutiny Over Gene Therapy Protocols: UniQure Faces FDA Challenges In a significant development for the gene therapy field, UniQure finds itself in a contentious standoff with the U.S. Food and Dr…
### Regulatory Challenges in Gene Therapy: A Call for Reform In recent discussions surrounding the FDA's role in the pharmaceutical industry, particularly at the CNBC Cures Summit in New York City, si…
BioMarin Expands Treatment Options for Adolescents with Phenylketonuria The U.S. Food and Drug Administration (FDA) has recently approved BioMarin Pharmaceutical Inc.'s supplemental application for Pa…
### BioMarin's Groundbreaking Approval of PALYNZIQ: A Game Changer for Pediatric PKU Treatment BioMarin Pharmaceutical Inc. recently achieves a pivotal milestone with the FDA's approval of PALYNZIQ® (…
Biomarin Pharmaceutical's Growth Trajectory Amidst Mixed Quarterly Results Biomarin Pharmaceutical Inc. finds itself at a pivotal juncture, as it reports its fourth-quarter results which reveal mixed…
BioMarin Pharmaceuticals Takes Center Stage at Key Healthcare Conferences BioMarin Pharmaceutical Inc., based in San Rafael, California, actively pursues its mission to enhance treatment options for r…
BioMarin Pharmaceutical Advances Commitment to Rare Disease Treatments at Upcoming Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reaffirms its dedication to revolutionizing care for rare dis…
Biomarin frames earnings day as a strategic program update Regulatory and Program Updates Take Center Stage Biomarin uses its Feb. 23, 2026 quarterly results as a vehicle to deliver updates on late-st…
Financing push ahead of Amicus purchase BioMarin Pharmaceutical is moving forward with a financing package to support its pending acquisition of Amicus Therapeutics, depositing gross proceeds from a n…
BioMarin Pharmaceuticals Appoints Chief Digital and Information Officer to Drive Digital Transformation BioMarin Pharmaceutical Inc. announces the appointment of Arpit Davé as its Executive Vice Presi…
BioMarin Pharmaceuticals and Veeva Systems Forge a Strategic Partnership to Accelerate Drug Development BioMarin Pharmaceutical Inc. and Veeva Systems have announced a long-term partnership aimed at e…
BioMarin and Veeva Forge Strategic Alliance to Enhance Therapeutic Development BioMarin Pharmaceutical Inc. has recently announced a significant expansion of its long-term enterprise agreement with Ve…
BioMarin Pharmaceutical Expands Portfolio with Acquisition of Amicus Therapeutics BioMarin Pharmaceutical Inc. announces a strategic acquisition of Amicus Therapeutics, Inc. in a deal valued at approx…
BioMarin Pharmaceutical Enhances Its Portfolio with Amicus Therapeutics Acquisition BioMarin Pharmaceutical Inc. announces a significant strategic move with its agreement to acquire Amicus Therapeutic…